Zoledronic Acid News and Research

RSS
Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa.
Study compares efficacy and side effects of popular osteoporosis drugs

Study compares efficacy and side effects of popular osteoporosis drugs

Risks of developing kidney failure, calcium deficiency from zoledronic acid are extremely rare

Risks of developing kidney failure, calcium deficiency from zoledronic acid are extremely rare

Atorvastatin drug plus zoledronic acid may help treat toxoplasmosis

Atorvastatin drug plus zoledronic acid may help treat toxoplasmosis

Zometa does not prevent bone metastases

Zometa does not prevent bone metastases

Dr. Reddy's launches generic Zometa

Dr. Reddy's launches generic Zometa

Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis medication Aclasta now available on Canadian public drug plans

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer

Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Osteoporosis drug protects against bone damaging side effects of breast cancer medications

Osteoporosis drug protects against bone damaging side effects of breast cancer medications

Zoledronic acid may extend survival in older breast cancer patients

Zoledronic acid may extend survival in older breast cancer patients

Zoledronic acid may benefit post-menopausal women with breast cancer

Zoledronic acid may benefit post-menopausal women with breast cancer

Zometa bone drug trial in post-menopausal women with breast cancer

Zometa bone drug trial in post-menopausal women with breast cancer

IRSF announces new Rett syndrome translational research awards

IRSF announces new Rett syndrome translational research awards

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.